Skip to contentpdufa.bio

Tapinarof (pediatric plaque psoriasis)

Page updated ·next FDA decision on the calendar ·Data as of Nov 21, 2026 10:10 PM ET

Tapinarof (pediatric plaque psoriasis) is an Organon & Co. program.

OGN catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: Organon & Co. (OGN). We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Oct 2026OGN

Questions

When is Tapinarof (pediatric plaque psoriasis)'s next FDA decision or readout?

No upcoming catalyst is on our calendar for Tapinarof (pediatric plaque psoriasis); no FDA decisions are on record below.

What happened at Tapinarof (pediatric plaque psoriasis)'s most recent FDA decision?

No FDA decision for Tapinarof (pediatric plaque psoriasis) is in our archive yet.

Who makes Tapinarof (pediatric plaque psoriasis)?

Organon & Co. (OGN).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.